The European Medicines Agency (EMA) recommended on Monday 6 December that the use of the anti-inflammatory drug RoActemra be extended to adult inpatients with severe Covid-19 “already receiving corticosteroid treatment and requiring supplemental oxygen or mechanical ventilation” (see EUROPE B12774A8).
This treatment, marketed by the German company Roche Registration GmbH, has been authorised in the EU since 2009 for the treatment of inflammatory diseases such as rheumatoid arthritis and...